Smart Pipeline Decisions: AI-Powered Indication Prioritization for Oncology TA

Background:

In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hundreds of potential cancers and limited resources, selecting the most promising therapeutic indications for early-stage assets is both critical and complex. Traditional prioritization methods usually rely on manual literature reviews, expert panels, and historical analogs, lagging to keep pace with the dynamic nature of clinical, regulatory, and market data, which in turn delays portfolio actions.

With a goal to address this challenge, one of our key clients sought a solution from us that would provide a systematic, multi-dimensional, and data-centric approach to prioritize oncology indications for their early-stage pipeline assets.

Objective:

The primary objective was to enable evidence-based indication prioritization by integrating epidemiological, clinical, and commercial datasets into a unified, AI-powered decision framework that would:

  • Identify high-value oncology indications with optimal market potential and strategic fit.
  • Accelerate go or no-go decisions in the asset development stage.
  • Balance scientific feasibility, unmet need, competitive intensity, and commercial viability.

Approach:

Thelansis deployed its own AI-powered cloud platform to support structured indication assessment through a combination of epidemiological insights mapping, clinical landscape intelligence, and market attractiveness scoring model.

Our team also developed simulation models to analyse various scenarios from launch to adoption, predicting ROI potential.

Our solution consolidated all the insights into interactive dashboards, providing real-time visualization.

Impact:

Through this technology-enabled framework, the client successfully transitioned from a subjective, time-intensive indication assessment process to a multi-dimensional, data-centric prioritization model. The key outcomes included:

  • 30% faster Therapy area/ indication selection cycle, reducing decision turnaround time from months to weeks.
  • Freed up over 400 hours of manual research and cross-team alignment.
  • Identification of three high-potential oncology indications with strong commercial viability and feasible development timelines.
  • Enhanced asset valuation by aligning development plans with high-impact indications.

With this approach, our client not only accelerated their decision-making process but also strengthened their scientific and commercial rationale for every pipeline move.


Read more: Smart Pipeline Decisions: AI-Powered Indication Prioritization for Oncology TA

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more